AlphaFold predicted structure
HTRA2 · O43464

Mean pLDDT
74.4/ 100
Confident
458 residues
Confidence breakdown
- Very high(≥ 90)52%
- Confident(70–90)12%
- Low(50–70)7%
- Very low(< 50)30%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
HtrA serine peptidase 2
Annotations refreshed 1 month ago.
Diagnostic Grade (Green)
Bilateral congenital or childhood onset cataracts
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
BIALLELIC, autosomal or pseudoautosomalCOVID-19 research
BIALLELIC, autosomal or pseudoautosomalEarly onset dystonia
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalMitochondrial disorders
BIALLELIC, autosomal or pseudoautosomal+10 more panels — install the extension to see the full list inline on any page.
3-methylglutaconic aciduria type 8
3-methylglutaconic aciduria
Young adult-onset Parkinsonism
Decreased total neutrophil count
neutropenia
hereditary disease
Leigh syndrome
autism
Parkinson disease
breast ductal adenocarcinoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Serine protease HTRA2, mitochondrial
Serine protease that shows proteolytic activity against a non-specific substrate beta-casein (PubMed:10873535). Promotes apoptosis by either relieving the inhibition of BIRC proteins on caspases, leading to an increase in caspase activity; or by a BIRC inhibition-independent, caspase-independent and serine protease activity-dependent mechanism (PubMed:15200957). Cleaves BIRC6 and relieves its inhibition on CASP3, CASP7 and CASP9, but it is also prone to inhibition by BIRC6 (PubMed:36758104, PubMed:36758105). Cleaves THAP5 and promotes its degradation during apoptosis (PubMed:19502560)
HTRA2 · O43464

Mean pLDDT
74.4/ 100
Confident
458 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0